Clinical trial NCT00848510: EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases
Official title: A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, PD and PK of EMD 525797 Using DCE-MRI as a PK Measure of Response in Colorectal and Ovarian Cancer Patients With Liver Metastases After Failure of Standard Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Colorectal and Ovarian Cancer Patients With Liver Metastases
Lead sponsor: Merck KGaA, Darmstadt, Germany
Sponsor class: INDUSTRY
First posted: 2009-02-20
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is intended to test an experimental drug called EMD 525797 (Abituzumab). This drug is not yet approved for sale and has only been tested in a small number of people to date (prior to this study starting another research study was carried out involving 37 healthy volunteers receiving the study drug). Until more is known about this study drug, it can only be used in research studies.

This research study is planned to answer important questions about how the study drug is tolerated and how it may work in subjects with ovarian and colorectal cancer which has spread to the liver (i.e. metastatic cancer). The Sponsor (Merck KGaA) of this study is developing the study drug.


Eligibility criteria: Inclusion Criteria:

* Provision of signed written informed consent
* Male or female subjects, aged at least 18 years
* Subjects with liver metastases (3 to 10 centimeter \[cm\] diameter) from colorectal and ovarian cancers
* Failure of standard cancer therapy
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at study entry and an estimated life expectancy of at least 3 months
* Adequate haematological function, defined by absolute neutrophil count (ANC) greater than or equal to (\>=) 1.5 x 10\^9 per liter (/L), platelet count \>= 100 x 10\^9 / L, and haemoglobin concentration \>= 9 gram per deciliter (g/dL)
* As subjects with documented liver metastases are treated in this trial, liver function test values are accepted as followed: up to the upper limit of Grade 2 as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0. This includes total bilirubin level less than or equal to (=\<) 3 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =\<5 x ULN
* Adequate renal function defined by serum creatinine =\<1.5 x ULN or a creatinine clearance of \>=50 milliliter per minute (mL/min) calculated by Cockcroft-Gault
* Effective contraception (example: double barrier method) for both male and female subjects if the risk of conception exists. These subjects must be willing to avoid pregnancy during the study (screening to end of study \[EOS\]) as well as for at least 3 months after the last dosing.

Exclusion Criteria:

* Any systemic cancer treatment within 30 days before treatment with EMD 525797
* Thrombolytics or oral or parenteral anticoagulants (except to maintain patency of preexisting, permanent indwelling intravenous catheters) within 10 days prior to study start and during treatment
* Radiotherapy, chemotherapy, surgery, or any investigational drug in the 30 days before the start of treatment in this study, and/or diagnostic biopsies within 2 weeks before the start of treatment in this study
* Previous treatment with anti-integrin therapy or anti angiogenic therapy within the last 6 months
* Confirmed or clinically suspected brain metastases
* Known hypersensitivity reactions to the study medication
* History of allergic reactions to other monoclonal antibody (mAb) therapy
* Uncontrolled hypertension (systolic blood pressure greater than (\>) 180 millimeter of mercury (mmHg), diastolic \>100 mmHg)
* Current history of chronic daily aspirin therapy (doses of =\< 150 mg is permitted), bleeding disorders, and/or history of thromboembolic events
* Severe peripheral vascular disease or ulceration
* Unstable angina pectoris, or myocardial infarction within 6 months before start of study treatment, clinical significant abnormal electrocardiogram (ECG) at screening;
* In women of childbearing potential, pregnancy (absence to be confirmed by beta human chorionic gonadotropin \[β HCG\] test, unless a subject has previously undergone hysterectomy or bilateral ovariectomy), or lactation period
* Known alcohol or drug abuse
* Participation in another clinical trial within the past 30 days before start of study treatment
* All other significant diseases which, in the opinion of the principal investigator (PI), might impair the subject's tolerance of study treatment
* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
* Legal incapacity or limited legal capacity (not applicable only in rare cases)
* Known human immuno deficiency (HIV) infection and/or active hepatitis B or C virus infections
* Ongoing uncontrolled infections
* Contraindications to magnetic resonance imaging (MRI)

Primary outcomes:
measure: Number of Subjects With Dose Limiting Toxicities (DLTs)
timeFrame: Up to Week 4
measure: Volume Transfer Coefficient of Contrast Agent Across the Capillary Walls
timeFrame: Screening 1, screening 2, Week 1 Day 2, Week 1 Day 5, and Week 2 Day 1
measure: Blood Plasma Volume and Extravascular/Extracellular Volume
timeFrame: Screening 1, screening 2, Week 1 Day 2, Week 1 Day 5, and Week 2 Day 1
measure: Initial Area Under the DCE-MRI Contrast Agent Concentration Time Curve After 60 Seconds (IAUC60)
timeFrame: Screening 1, screening 2, Week 1 Day 2, Week 1 Day 5, and Week 2 Day 1
measure: Whole Tumor Volume and Enhancing Tumor Volume
timeFrame: Screening 1, screening 2, Week 1 Day 2, Week 1 Day 5, and Week 2 Day 1
Secondary outcomes:
measure: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death
timeFrame: From the initiation of the trial treatment until 30 days after last administration of trial treatment.
measure: Number of Subjects With Best Overall Response, Tumor Response and Clinical Benefit
timeFrame: Up to 4 years
measure: Number of Subjects With Worsened Post Baseline Shift in ECOG Performance Status Score
timeFrame: Up to 4 weeks after last dose administration
measure: Number of Subjects With Positive Binding Abituzumab Antibodies
timeFrame: Day 1 of Weeks 1, 3, 5, 6, 7, 8, and week 11 and end of study (EOS) visit (4 weeks after last dose administration)
measure: Progression-Free Survival (PFS) Time
timeFrame: Time from first study drug intake to disease progression, death or last tumor assessment until end of trial visit (4 weeks after last dose administration)
Other outcomes:
Locations:
city: Manchester
country: United Kingdom
facility: Christie Hospital
Study officials:
affiliation: Merck KGaA, Darmstadt, Germany
name: Medical Responsible
role: STUDY_DIRECTOR
References: